Elevated uric acid levels are predictive of
one-year mortality in patients with acute coronary syndrome, according to a
study published in the May 1 issue of The American Journal of Cardiology.
Gjin
Ndrepepa, M.D., of the Deutsches Herzzentrum in Munich, Germany, and colleagues
conducted a study involving 5,124 patients with acute coronary
syndrome who underwent percutaneous coronary intervention (PCI) to
evaluate whether uric acid levels have any prognostic value in this patient
population.
Of the
participants, 1,629 had acute ST-segment elevation myocardial
infarction (STEMI), 1,332 had acute non-STEMI, and 2,163 had unstable angina.
Participants were classified into four uric acid quartiles: quartile 1 (1.3 to
<5.3 mg/dL), quartile 2 (5.3 to <6.3 mg/dL), quartile 3 (6.3 to <7.5
mg/dL), and quartile 4 (7.5 to 18.4 mg/dL). One-year mortality was the primary
end point.
During
follow-up, the researchers identified 450 deaths: 80 deaths in quartile 1, 77
in quartile 2, 72 in quartile 3, and 221 in quartile 4 (unadjusted hazard
ratio, 3.05 for fourth versus first quartile uric acid).
The
association between uric acid and mortality persisted after adjustment, with
every 1-mg/dL increase in the uric acid level correlating with a 12 percent
increase in the adjusted risk for one-year mortality.
"Elevated
levels of uric acid are an independent predictor of one-year mortality across
the whole spectrum of patients with acute coronary syndromes treated with
percutaneous coronary intervention," the authors write.
More
information: The
American journal of cardiology, 1 May 2012, v. 109, 9 , pp. 1260-1265. DOI: 10.1016/j.amjcard.2011.12.018)
Copyright
© 2012 HealthDay. All rights reserved.
No comments:
Post a Comment